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Surgery After Induction Chemotherapy or
Chemoradiotherapy for Locally Advanced Lung Cancer
A Technical Challenge
Hisao Asamura, MD
The optimal management of the patients with clinical stage IIIA disease (especiallyIIIA-N2 disease) has not been clearly defined. Those who have had questionable
lymph nodes for metastasis by chest computed tomography or positron emission tomog-
raphy scan should undergo a mediastinal evaluation via endobronchial ultrasound bron-
choscopy or cervical mediastinoscopy for the cytologic/histologic confirmation of clinical
N2 disease. Although it has been widely accepted that the upfront surgery for patients with
a proven N2 disease does not improve their survival and the concurrent chemoradiother-
apy is respected as the standard management for these patients, the significance of the
surgical intervention of this scenario has not been well established.1,2
In the present issue of Journal of Thoracic Oncology, important results on the
outcome of surgical interventions after induction chemotherapy or chemoradiotherapy for
non-small cell lung cancer (NSCLC) have been reported from the Memorial Sloan-
Kettering Cancer Center in New York.3 This retrospective analysis is the largest single-
institution experience in the literature with 549 patients who underwent surgical resection
after chemotherapy alone (83%) or chemoradiotherapy (17%). The in-hospital mortality
was 1.8% (10 of 549), and the predicted postoperative (PPO) pulmonary function was
associated with postoperative morbidity. The authors concluded that that the resection of
NSCLC after induction therapy is feasible with low mortality and that PPO pulmonary
function should be used in selecting the candidates for surgery. This important report
provides us with benchmark data regarding the postoperative morbidity/mortality of
surgery after induction treatment. The outcome clearly shows that this especially chal-
lenging surgery can be performed safely at an experienced center.
However, we must consider two issues that are relevant to the nature of the
combined modality treatment approach with surgery after induction treatment. They are
the objective risk of pneumonectomy and the influence of the inclusion of radiotherapy in
the induction treatment on the development of postoperative complications.
In our previous retrospective study on the incidence, risk factors, and management
of the bronchopleural fistula (BPF), prior radiation treatment was one of the significant
risk factors for BPF together with pneumonectomy, R1 operation, and diabetes.4 There-
fore, the addition of radiation to the systemic chemotherapy in the induction treatment is
reasonably expected to increase the risk after operation. Cerfolio et al.5 retrospectively
studied 104 patients who had the pulmonary resection following low-dose (50 patients)
and high-dose radiation (54 patients). They reported that mortality rate for the low-dose
radiation group and high-dose radiation group were 2% and 3.7%, respectively. However,
for the 12 patients undergoing pneumonectomy, the mortality rate was 16.7%. Daly et al.6
also reported the similar mortality rate of 13.3% after pneumonectomy following high-
dose radiation therapy. Although they concluded that pneumonectomy should continue
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even with such high operative mortality rate, there must be an
acceptable balance between the oncological benefit and op-
erative risk especially when performing a pneumonectomy.
In the present article from the Memorial Sloan-Ketter-
ing group, the authors reported that the mortality rate after
pneumonectomy with/without preoperative radiation therapy
was only 4.3%.3 However, even in the same institute, the
mortality rate in a previous report was as high as 11.3%, but
now they report a dramatic reduction in mortality rate in the
present report of 4.3%.7 The authors did not clearly identify
the reason(s) for this improvement, but they suggested sev-
eral possibilities: fewer indications for pneumonectomy in the
recent series because of the decrease of centrally located
squamous cell carcinomas and more “careful” attitude of
surgeons/physicians/radiation oncologist in selecting the pa-
tients. Contrary to the present and other series in favor of
pneumonectomy, some surgeons are still conservative in
performing this extensive procedure. Doddoli et al.8 analyzed
100 patients who underwent pneumonectomy after induction
therapy (both chemotherapy alone and chemoradiotherapy).
They observed that the 30- and 90-day mortality rates were
12% and 21%, respectively. They mentioned age older than
60 years, male sex, postoperative respiratory event, and
postoperative cardiovascular event as significant predictive
factors for 90-day mortality. They have concluded that pneu-
monectomy after induction therapy is a high-risk procedure,
the survival benefit of which appears uncertain.
The risk of pneumonectomy has been, in its nature,
generally higher than that of lobectomy. We have reported
0.3% as the 30-day mortality rate for lobectomy and 3.1% for
pneumonectomy.9 With pneumonectomy, we must obliterate
the prominent bronchial structure at the hilum, leaving a large
residual space behind, and there must be the drastic change in
the hemodynamics. Especially on the right side where the
main stem bronchus is shorter, and the resected end of the
bronchus is directly exposed to the residual free space. It is
widely accepted among thoracic surgeons that these anatom-
ical characteristics are responsible for the higher incidence of
bronchopleural fistula after the right-side pneumonectomy.
Of interest is how the Sloan-Kettering group has succeeded in
reducing the mortality rate for such challenging operations.
There must be something unwritten in their practice and
hidden between the lines in their report which is difficult to
translate to the written page.
Finally, I think that it is necessary to express a word of
caution. As stated earlier, this is an important benchmark
publication in the thoracic oncological community, and we
will continue to evaluate this report and compare it with
future publications. However, we should realize that these
outcomes came from a very experienced center, and that the
authors stated they also experienced a learning curve to
reduce the operative mortality rate after pneumonectomy
following induction therapy from 11.3 to 4.3%. Inexperi-
enced surgeons or institutions should consider that this high-
risk surgery is unlikely to be performed at the same mortality
rate as noted in this article. Integration of the written and
unwritten skills, know-hows, and technical knowledge is
indispensable. Surgery, especially pneumonectomy, after in-
duction chemotherapy or chemoradiotherapy should be ap-
proached cautiously with thoughtful consideration of postop-
erative morbidity and mortality.
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